Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist ¹⁷⁷Lu-Satoreotide Tetraxetan.

ABSTRACT:

Purpose

Radiolabeled somatostatin receptor 2 (SSTR2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than somatostatin agonists in preclinical models of neuroendocrine tumors (NETs). We performed a phase I study to evaluate the safety and efficacy of SSTR2 antagonist ¹⁷⁷Lu-satoreotide tetraxetan.

Patients and methods

Twenty patients with advanced SSTR2-positive NETs were treated with ¹⁷⁷Lu-satoreotide tetraxetan. Patients first underwent a dosimetry study with ¹⁷⁷Lu-satoreotide tetraxetan to determine the therapeutic activity that could be safely administered. This activity was split into two equal cycles to be delivered 3 months apart. The maximum activity was 7.4 GBq per cycle.

Results

Of 20 patients with NETs (o

SUBMITTER: Reidy-Lagunes D 

PROVIDER: S-EPMC8382090 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature